Peter Attia· MD
it turns out those two diseases uh were uniquely responsive and we now know at least for melanoma why that that's the case and that is the immune system is recognizing the products of mutations in melanoma
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
it turns out those two diseases uh were uniquely responsive and we now know at least for melanoma why that that's the case and that is the immune system is recognizing the products of mutations in melanoma
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
it was uh the first patient that we uh that we treated with this revised regimen happened to have a melanoma uh the third and fourth patients had renal cancer